摘要
糖尿病视网膜病变(DR)是糖尿病微血管并发症之一,严重的糖尿病黄斑水肿或增生性视网膜病变可导致糖尿病患者视力受损甚至失明。胰高血糖素样肽-1受体激动剂(GLP-1RA)作为新型降糖药物目前普遍应用于2型糖尿病的临床治疗,但GLP-1RA使用期间带来血糖的快速变化可能存在短期潜在DR发生增加的风险。其对于DR的潜在影响和机制包括氧化应激、血管内皮生长因子、炎症、视网膜神经变性和其他细胞因子。GLP-1RA是否导致DR风险增加的争议仍较大。未来仍需要更多基础和临床研究以期进一步明确GLP-1RA与DR风险的相关性。
Diabetic retinopathy(DR)is one of the most serious complications of diabetes mellitus.Severe diabetic macular edema or proliferative retinopathy may lead to impaired vision or even blindness in diabetic patients.The glucagon-like peptide-1 receptor agonist(GLP-1RA)is now commonly used as novel glucose-lowering agents in the clinical management of type 2 diabetes,but the rapid glycaemic changes associated with the use of the GLP-1RA may aggravate the risk of an increase in the occurrence of short-term potential DR.Potential effects and mechanisms of DR include oxidative stress,vascular endothelial growth factor,inflammation,retinal neurodegeneration,and other cytokines.Whether GLP-1RA leads to the increased risk of DR remains controversial.More basic and clinical studies are needed with the aim of further clarifying the correlation between GLP-1RA and DR risk.
作者
谭惠文
李丹婷
张美霞
Tan Huiwen;LiDanting;Zhang Meixia(Department of Endocrinology and Metabolism,West China Hospital,Sichuan University,Chengdu 610041,China;Department of Ophthalmology,West China Hospital,Sichuan University,Chengdu 610041,China)
出处
《中华眼底病杂志》
CAS
CSCD
北大核心
2023年第11期943-948,共6页
Chinese Journal of Ocular Fundus Diseases
基金
国家自然科学基金(81070675)
四川省科技厅科技项目(2016SZ0058)
四川省科技厅干保项目(YBGBKT22014)。
